Australia markets open in 3 hours 1 minute

Poxel S.A. (PXXLF)

OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
0.7000+0.1550 (+28.44%)
At close: 09:45AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.5450
Open0.7000
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.7000 - 0.7000
52-week range0.5450 - 2.6000
Volume100
Avg. volume1
Market cap27.022M
Beta (5Y monthly)1.55
PE ratio (TTM)N/A
EPS (TTM)-1.1600
Earnings date29 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Poxel Reports Revenue for the First Quarter 2024 and Provides Corporate Update

    LYON, France, May 16, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today reported its revenue for the quarter ended March 31, 2024 and provided a business update.

  • Business Wire

    Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release

    LYON, France, April 29, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today reported its cash position, provided a financial and business update for the first quarter ended March 31, 2024, and announced the postponement of its 2023 full-year results re

  • Business Wire

    Poxel to Report Its 2023 Annual Results by the End of April 2024

    LYON, France, March 28, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announces the publication at the end of April 2024 of its 2023 Annual Results, originally scheduled for April 9, 2024, given the expected completion of a transaction by the end of April.